Ischemic preconditioning reduces infarct size in patients treated with primary angioplasty

Original title: Preinfarction Angina Reduces Infarct Size in ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention Reference: Ronald Reiter et al. Circ Cardiovasc Interv. 2013;6:00-00.

Ischemic preconditioning (IPC) is a phenomenon whereby transitory ischemia episodes protect the myocardium against a more prolonged episode. 

Until now, IPC has been the most effective approach to protect the myocardium. Pre infarction angina is a clinical surrogate of IPC and has been associated with reduced infarct size in patients that receive thrombolytic therapy; however this is not conclusive for patients treated with primary angioplasty.

245 patients with ST elevation myocardial infarction treated with primary angioplasty were analyzed; 79 of these patients had presented angina 24 hours before admition vs. 166 patients without pre infarction angina. There were no significant differences in the rest of baseline characteristics between both groups.

For the patients with previous angina, both infarct size and troponin peak was significantly reduced (p<0,0001) despite having identical ischemic times and angiographic results. Ejection Fraction was 4$ lower in patients with preconditioning (51,4±1,1% vs. 47,5±1%; p=0,02).

Conclusion 

This study is the most detailed analysis carried out so far on the potential protective effect of ischemic preconditioning in patients with ST elevation myocardial infarction treated with primary angioplasty.

Editorial Comment

Randomized studies on ST elevation acute coronary syndromes should start considering pre infarction angina among key variables, seeing that this could be an important confounder, mainly if infarct size is one of the primary concerns. A good example of this is the large number of trials assessing the use of thrombi aspiration.

SOLACI.ORG

More articles by this author

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

Drugs for the Treatment of No-Reflow During PCI

The no-reflow phenomenon is one of the most frustrating complications of primary angioplasty (pPCI), reflecting persistent microvascular damage that, in the mid- to long-term,...

Rotational atherectomy and its technical secrets: use of floppy or ES guidewire

Rotational atherectomy (RA) remains a very useful tool in the management of severe coronary calcification. However, many of its technical aspects rely more on...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACVC 2026 | CELEBRATE Trial: Prehospital Zalunfiban Use in STEMI

Optimizing antithrombotic therapy in the prehospital phase of ST-segment elevation myocardial infarction (STEMI) remains challenging due to the delayed onset of action of P2Y12...

ACVC 2026 | BOX Substudy: Mean Arterial Pressure Targets in Cardiogenic Shock After OHCA

Hemodynamic management of cardiogenic shock following ischemic out-of-hospital cardiac arrest (OHCA-AMICS) remains an unresolved issue, particularly regarding optimal mean arterial pressure (MAP) targets and...

ACVC 2026 | FLASH Registry European Cohort: Mechanical Thrombectomy in Pulmonary Embolism

The management of intermediate-high and high-risk pulmonary embolism (PE) remains an area of therapeutic uncertainty, particularly in patients with right ventricular (RV) dysfunction, in...